• 1
    Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
  • 2
    Nathwani BN, Anderson JR, Armitage JO, et al. Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1999; 17: 2486-2492.
  • 3
    Gill H, Chim CS, Au WY, et al. Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment results. Ann Hematol. 2011; 90: 1399-1407.
  • 4
    Kahl B, Yang D. Marginal zone lymphomas: management of nodal, splenic, and MALT NHL. Hematology Am Soc Hematol Educ Program. 2008: 359-364.
  • 5
    Parry-Jones N, Matutes E, Gruszka-Westwood AM, Swansbury GJ, Wotherspoon AC, Catovsky D. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol. 2003; 120: 759-764.
  • 6
    Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma. 2002; 3: 41-47.
  • 7
    Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000; 95: 1950-1956.
  • 8
    Brown JR, Friedberg JW, Feng Y, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009; 145: 741-748.
  • 9
    Arcaini L, Lucioni M, Boveri E, Paulli M. Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease. Eur J Haematol. 2009; 83: 165-174.
  • 10
    Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003; 102: 2741-2745.
  • 11
    Kang HJ, Kim WS, Kim SJ, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol. 2012; 91: 543-551.
  • 12
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub (1973-2009 varying)-Linked To County Attributes-Total US, 1969-2010 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2012, based on November 2011 submission. Accessed April 19, 2012.
  • 13
    North American Association of Central Cancer Registries Race and Ethnicity Work Group. NAACCR Guideline for Enhancing Hispanic/Latino Identification. Accessed April 26, 2012.
  • 14
    Turner JJ, Morton LM, Linet MS, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood. 2010; 116: e90-e98.
  • 15
    Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst. 2010; 102: 1584-1598.
  • 16
    Pintilie M. Competing Risks: A Practical Perspective. Chichester, UK: John Wiley & Sons Ltd; 2006.
  • 17
    Gray R. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 1141-1154.
  • 18
    Dignam JJ, Zhang Q, Kocherginsky M. The use and interpretation of competing risks regression models. Clin Cancer Res. 2012; 18: 2301-2308.
  • 19
    Gray R. cmprsk: Subdistribution Analysis of Competing Risks. R package. Version 2.2-2. Vienna, Austria: R Foundation for Statistical Computing; 2011. Accessed July 27, 2012.
  • 20
    Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006; 107: 265-276.
  • 21
    Wu XC, Andrews P, Chen VW, Groves FD. Incidence of extranodal non-Hodgkin lymphomas among whites, blacks, and Asians/Pacific Islanders in the United States: anatomic site and histology differences. Cancer Epidemiol. 2009; 33: 337-346.
  • 22
    Morton LM, Wang SS, Cozen W, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood. 2008; 112: 5150-5160.
  • 23
    Mazloom A, Medeiros LJ, McLaughlin PW, et al. Marginal zone lymphomas: factors that affect the final outcome. Cancer. 2010; 116: 4291-4298.
  • 24
    Zucca E, Conconi A, Pedrinis E, et al; International Extranodal Lymphoma Study Group. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003; 101: 2489-2495.
  • 25
    Borie R, Wislez M, Thabut G, et al. Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. Eur Respir J. 2009; 34: 1408-1416.
  • 26
    Arcaini L, Burcheri S, Rossi A, et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist. 2006; 11: 285-291.
  • 27
    Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010; 116: 3815-3824.
  • 28
    Tsai HK, Li S, Ng AK, Silver B, Stevenson MA, Mauch PM. Role of radiation therapy in the treatment of stage I/II mucosa-associated lymphoid tissue lymphoma. Ann Oncol. 2007; 18: 672-678.
  • 29
    Farinha P, Gascoyne RD. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol. 2005; 23: 6370-6378.
  • 30
    Salido M, Baro C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood. 2010; 116: 1479-1488.
  • 31
    Rinaldi A, Mian M, Chigrinova E, et al. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood. 2011; 117: 1595-1604.
  • 32
    Troch M, Wohrer S, Raderer M. Assessment of the prognostic indices IPI and FLIPI in patients with mucosa-associated lymphoid tissue lymphoma. Anticancer Res. 2010; 30: 635-639.
  • 33
    Oh SY, Kwon HC, Kim WS, et al. Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study. Cancer Lett. 2007; 258: 90-97.
  • 34
    Arcaini L, Lazzarino M, Colombo N, et al; Integruppo Italiano Linfomi. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006; 107: 4643-4649.
  • 35
    Arcaini L, Paulli M, Burcheri S, et al; Intergruppo Italiano Linfomi. Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol. 2007; 136: 301-304.
  • 36
    Kojima M, Inagaki H, Motoori T, et al. Clinical implications of nodal marginal zone B-cell lymphoma among Japanese: study of 65 cases. Cancer Sci. 2007; 98: 44-49.
  • 37
    Raderer M, Wohrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol. 2006; 24: 3136-3141.
  • 38
    Papaxoinis G, Fountzilas G, Rontogianni D, et al. Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2008; 19: 780-786.
  • 39
    Montalban C, Castrillo JM, Abraira V, et al. Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. Ann Oncol. 1995; 6: 355-362.